Canaccord analyst Sumant Kulkarni said the key updates in Q4 for Stoke Therapeutics (STOK) were that the company is set to start its Phase 3 EMPEROR trial in 2Q25 after reaching alignment earlier with regulatory agencies, and that CEO Ed Kaye is stepping down. Canaccord believes the company is well capitalized but significantly undervalued. Canaccord maintains its Buy rating and $20 price target on Stoke Therapeutics shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics: Buy Rating Affirmed Amid Strategic Developments and Strong Financial Position
- Stoke Therapeutics Advances with Strong Financial Position
- Optimistic Buy Rating for Stoke Therapeutics Driven by Promising Clinical Trials and Strategic Developments
- Stoke Therapeutics: Promising Phase 3 Trial and Strategic Leadership Transition Bolster Buy Rating
- Positive Outlook for Stoke Therapeutics: Buy Rating Backed by Strong Leadership Transition, Robust Financial Position, and Promising Phase 3 Trial